Efficacy of pregabalin in generalized social anxiety disorder: Results of a double-blind, placebo-controlled, fixed-dose study

International Clinical Psychopharmacology

Volumn 26, Issue 4, 2011, Pages 213-220

  Feltner, Douglas E ^a   Liu Dumaw, Maria ^c   Schweizer, Edward ^d   Bielski, Robert ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Michigan State University   (United States)

^c MLD Consulting   (United States)

^d Paladin Consulting Group   (United States)

Author keywords

Anxiety disorders; Phobic disorders; Pregabalin; Social anxiety disorder

Indexed keywords

PLACEBO; PREGABALIN;

ABNORMAL THINKING; ADULT; AMNESIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LIEBOWITZ SOCIAL ANXIETY SCALE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SCORING SYSTEM; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051548249     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834519bd     Document Type: Article

References (48)

1. Allgulander C (1999). Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100:193-198. (Pubitemid 29409085)
2. Alonso J, Lé pine JP; ESEMeD/MHEDEA 2000 Scientific Committee (2007). Overview of key data from the European study of the epidemiology of mental disorders (ESEMeD). J Clin Psychiatry 68 (Suppl 2):3-9.
3. Baldwin D, Bobes J, Stein DJ, Scharwächter I, Faure M (1999). Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebocontrolled study, paroxetine study group. Br J Psychiatry 175:120-126. (Pubitemid 29359373)
4. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312.
5. Bech P (2007). Dose-response relationship of pregabalin in patients with generalized anxiety disorder: a pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40:163-168. (Pubitemid 47434876)
6. Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, et al. (2006). Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an exvivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 1075:68-80.
7. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. (2005). Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:1179-1187. (Pubitemid 40770702)
8. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, Van der Hoop RG, et al. (2004). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:118-125. (Pubitemid 38380834)
9. Fehm L, Pelissolo A, Furmark T, Wittchen HU (2005). Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 15:453-462. (Pubitemid 40949552)
10. Grant BF, Hasin DS, Blanco C, Stinson FS, Chou SP, Goldstein RB, et al. (2005). The epidemiology of social anxiety disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 66:1351-1361. (Pubitemid 41779531)
11. Guy W (1976). ECDEU assessment manual for psychopharmacology. Rockville, MD: US Dept of Health, Education and Welfare. Hamilton MA (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Hamilton MA (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM (2007). The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 21:102-111. (Pubitemid 46012089)
14. Heimberg RG (2002). Cognitive-behavioral therapy for social phobia: current status and future directions. Biol Psychiatry 51:101-108. (Pubitemid 34093798)
15. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, et al. (1999). Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 29:199-212. (Pubitemid 29034537)
16. Hidalgo RB, Tupler LA, Davidson JR (2007). An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864-872. (Pubitemid 350029180)
17. Hochberg Y (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802.
18. Ipser JC, Kariuki CM, Stein DJ (2008). Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 8:235-257. (Pubitemid 351281112)
19. Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222-226. (Pubitemid 40343816)
20. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, et al. (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24:87-96.
21. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
22. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ (2002). Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257-262. (Pubitemid 34546840)
23. Lader M, Stender K, Bü rger V, Nil R (2004). Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241-248. (Pubitemid 39014144)
24. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L (2004). Controlledrelease paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65:222-229.
25. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD (2002). A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63:66-74. (Pubitemid 34113490)
26. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785-792. (Pubitemid 36897215)
27. Lozsadi D, Hemming K, Marson AG (2008). Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 1:CD005612.
28. Lydiard RB, Bobes J (2000). Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depress Anxiety 11:99-104. (Pubitemid 30347185)
29. Marks I, Mathews A (1979). Brief standard self-rating for phobic patients. Behav Res Ther 17:263-267. (Pubitemid 10232022)
30. Montgomery SA, Kasper S (2010). Pharmacotherapy update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Ther 2:189-202.
31. Montgomery SA, Nil R, Dü rr-Pal N, Loft H, Boulenger JP (2005). A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270-1278. (Pubitemid 41546506)
32. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ (2009). Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 3:CD007076.
33. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. (1999). Treatment of social phobia with gabapentin: a placebocontrolled study. J Clin Psychopharmacol 19:341-348. (Pubitemid 29344848)
34. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141-149. (Pubitemid 38380837)
35. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25:151-158. (Pubitemid 40395093)
36. Rodebaugh TL, Holaway RM, Heimberg RG (2004). The treatment of social anxiety disorder. Clin Psychol Rev 24:883-908. (Pubitemid 39388876)
37. Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC (2008). Social fears and social phobia in the USA: results from the national comorbidity survey replication. Psychol Med 38:15-28. (Pubitemid 350275216)
38. SAS/Stat User's Guide (1989). Volumes 1 and 2, version 6.0. Cary, NC: SAS Institute.
39. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33. (Pubitemid 29001829)
40. Steel R, Torrie J (1980). Principles and procedures of statistics. New York: McGraw-Hill Book Co. Inc. pp. 113-119.
41. Stein MB, Fyer AJ, Davidson JRT, Pollack MH, Wiita B (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebocontrolled study. Am J Psychiatry 156:756-760. (Pubitemid 29220075)
42. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998). Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280:708-713. (Pubitemid 28405295)
43. Swinson RP; Clinical Practice Guideline Working Group (2006). Management of anxiety disorders. Can J Psychiatry 51:1S-92S.
44. Taylor CP, Angelotti T, Fauman E (2007). Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73:137-150. (Pubitemid 46329329)
45. Van Vliet IM, den Boer JA, Westenberg HGM (1994). Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 115:128-134. (Pubitemid 24207772)
46. Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB (2005). Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 22:59-67. (Pubitemid 41598041)
47. Ware JE Jr, Snow KK, Kosinski M, Gandek B (1993). SF-36 Health Survey: manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center.
48. Yonkers KA, Bruce SE, Dyck IR, Keller MB (2003). Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety 17:173-179. (Pubitemid 36644715)